cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Myriad Genetics Inc
5 own
6 watching
Current Price
$24.99
$-0.3
(-1.19%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,888.71M
52-Week High
52-Week High
25.95000
52-Week Low
52-Week Low
13.82000
Average Volume
Average Volume
0.65M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
22.73
iconMarket Capitalization1,888.71M
icon52-Week High25.95000
icon52-Week Low13.82000
iconAverage Volume0.65M
iconDividend Yield--
iconP/E Ratio22.73
What does the Myriad Genetics Inc do?
Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease; identify a patient's likelihood of responding to drug therapy; guide a patient's dosing to ensure optimal treatment; and assess a patient's risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS test for colorectal and uterine cancers; COLARIS AP test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for prostate cancer; EndoPredict RNA expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; myChoice homologous recombination deficiency (HRD) test to measure three modes of HRD; and myPlan lung cancer, an RNA expression test for lung cancer. Myriad Genetics, Inc. has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
How much money does Myriad Genetics Inc make?
News & Events about Myriad Genetics Inc.
Globe Newswire
11 months ago
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and responseSALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The ...
Globe Newswire
1 year ago
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient careSALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed Imaging, one of ...
Ticker Report
1 year ago
Myriad Genetics, Inc. (NASDAQ:MYGN Get Rating) COO Nicole Lambert sold 6,433 shares of the companys stock in a transaction dated Monday, March 27th. The shares were sold at an average price of $23.48, for a total transaction of $151,046.84. Following the completion of the transaction...
Zolmax
1 year ago
Myriad Genetics, Inc. (NASDAQ:MYGN Get Rating) COO Nicole Lambert sold 6,433 shares of the companys stock in a transaction dated Monday, March 27th. The shares were sold at an average price of $23.48, for a total transaction of $151,046.84. Following the completion of the transaction...
Globe Newswire
1 year ago
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industrySALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (...
Frequently Asked Questions
Frequently Asked Questions
What is Myriad Genetics Inc share price today?
plus_minus_icon
Can Indians buy Myriad Genetics Inc shares?
plus_minus_icon
How can I buy Myriad Genetics Inc shares from India?
plus_minus_icon
Can Fractional shares of Myriad Genetics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Myriad Genetics Inc stocks?
plus_minus_icon
What is today’s traded volume of Myriad Genetics Inc?
plus_minus_icon
What is today’s market capitalisation of Myriad Genetics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Myriad Genetics Inc?
plus_minus_icon
What percentage is Myriad Genetics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Myriad Genetics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$24.99
$-0.3
(-1.19%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00